Author

Hilary Elaine Nicholson

Tango Therapeutics (United States)ORCID 0000-0002-3393-3013Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1

Frequent Co-Authors

Alan HuangiD· 1 shared Ashley H. ChoiiD· 1 shared Binzhang SheniD· 1 shared Charlotte B. PrattiD· 1 shared Chengyin MiniD· 1 shared Eden N. Gordon· 1 shared Hannah StoweiD· 1 shared Helena N. Jenkins· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alan HuangORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Tumor suppressor collateral damage screens reveal mRNA homeostasis protein HBS1L as a novel vulnerability in ch9p21 driven FOCAD deleted cancer

Hongxiang Zhang, Matthew R. Tonini, Lauren Catherine M. Martires, Helena N. Jenkins, Charlotte B. Pratt, Eden N. Gordon, Shan-Chuan Zhao, Ashley H. Choi, Samuel R. Meier, Tenzing Khendu, Shangtao Liu, Binzhang Shen, Hannah Stowe, Katerina Pashiardis, Xuewen Pan, , Teng Teng

The paper identifies HBS1L as a synthetic lethal target in FOCAD-deleted cancer through combinatorial CRISPR screens and validates its dependency via genetic manipulation and in vivo experiments.

Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · Oct 15, 2025Peer-reviewedCancer Biology